Sign in
Jeffrey Leiden
Photo: Theron Wallis, CC BY-SA 4.0, via Wikimedia Commons33

Jeffrey Leiden

CEO of biotechnology company

Jeffrey Leiden is an American physician, scientist and businessman who is the executive chairman of Vertex Pharmaceuticals, a biotechnology company based in Boston, Massachusetts. He was initially appointed to the board of directors of the company in 2009 and was CEO and president from February 2012 to March 2020.2

From Wikipedia’s article on Jeffrey Leiden (this version), CC BY-SA 4.0.

Born Oct 12, 1955.1

Companies

Holdings

Stock this person has reported owning, from the forms officers and directors file with the SEC. See the biggest insider stakes.

Shares held

As of each latest filing. The line shows shares held over time.

Recent filings

Early life and education

  • 1975University of Chicago bachelor's degree; biology3
  • 1979University of Chicago Doctor of Medicine3
  • 1981University of Chicago Doctor of Philosophy; virology3

Early life

Leiden grew up in Glencoe, a suburb north of Chicago. His mother was a primary school teacher, and his father was a clinical psychologist with a PhD in psychology. He has one sister. His grandparents on his mother’s side were Russian immigrants. At ten years old he learned to scuba dive, and by eleven he was a certified scuba instructor.

Education

Leiden attended a progressive public school in Glencoe, IL called North School which had a special self-paced learning program. In elementary school Leiden skipped second grade and started the University of Chicago after his junior year at New Trier East High School, at the age of 15.

He received his bachelor's degree in biological sciences at age 18, a Ph.D. in virology at age 21 and his M.D. at age 23 from the University of Chicago, where he later became Chief of Cardiology. He was elected to several honors societies, including Phi Beta Kappa and Alpha Omega Alpha. Between 1982 and 1987, Leiden was a clinical fellow in cardiology at the Brigham and Women’s Hospital, the Harvard Medical School and a postdoctoral fellow in medicine at the Dana–Farber Cancer Institute.

From Wikipedia’s article on Jeffrey Leiden (this version), CC BY-SA 4.0.

Career

Occupation: business executive, physician.10

In 1987, Leiden was appointed assistant professor of medicine and assistant investigator in the Howard Hughes Medical Institute at the University of Michigan in Ann Arbor.

In 1992, Leiden moved to the University of Chicago as the Rawson Professor of Medicine and Pathology and chief of the Division of Cardiology.

In 1996, Leiden, along with Elizabeth and Gary Nabel founded Cardiogene, a gene therapy company, which was subsequently acquired by Boston Scientific.

In 1999, Leiden was appointed the Elkin Blout Professor of Biological Sciences at the Harvard School of Public Health and Professor of medicine at the Harvard Medical School.

Leiden moved to Abbott Labs in June 2000, as senior vice president and chief scientific officer. Later that year, he was promoted to president and chief operating officer and oversaw all aspects of the company’s global pharmaceutical business, where he led the development and launch of Kaletra and Humira.

In 2006, Leiden joined Clarus Ventures as a managing director. At Clarus, Leiden founded and chaired the boards of Lycera Corporation and Variation Biotechnologies, and served as chairman of the board of TyRx, Inc., which was subsequently acquired by Medtronic (NYSE: MDT).

Read more

Vertex

Leiden served as chairman, president and chief executive officer of Vertex from 2012 to 2020. Under his leadership, Vertex developed and launched Kalydeco, Orkambi, Symdeko and Trikafta – the first medicines to treat the underlying cause of cystic fibrosis. The FDA approved Trikafta on October 21, 2019.

In 2015 Leiden established a collaboration between Vertex and CRISPR Therapeutics that led to the discovery and development of Casgevy, (exagamglogene autotemcel; formerly known as CTX001), the first gene editing treatment to show curative potential for two human genetic diseases, sickle cell disease and beta thalassemia. Casgevy was approved for use in the UK (November 2023), the United States (January 2024) and Europe, (February 2024.)

In 2015 Vertex shareholders voted to recommend reducing Leiden's compensation from its 2014 estimated figure of US$48.5 million. By 2017 his earnings totaled approximately US$17.3 million. Also under his leadership, Vertex acquired Semma Therapeutics for $950 million in 2019. The company developed stem cell-derived therapies including the experimental cell therapy for Type 1 diabetes known as VX-880.

Criticism of Vertex pricing structures for Orkambi, a groundbreaking cystic fibrosis drug costing in the region of US$135,000 to US$270,000 per patient per year depending on the patient's country, has resulted in campaigns by concerned parent groups addressed to Leiden. Leiden wrote to the UK Prime Minister Theresa May in 2018, suggesting Vertex might consider reducing investment in the UK as a result of the lack of agreement between Vertex and the UK's National Health Service on the pricing of a five-year access agreement for Vertex drugs.

On October 24, 2019, Vertex reached an agreement with NHS England for all currently licensed Vertex cystic fibrosis medicines, having previously reached similar agreements with countries including Scotland, Ireland and France. On June 20, 2024, the National Institute for Health and Care Excellence, (NICE) said in its final draft guidance that Orkambi, Symkevi, and Kaftrio are recommended for the treatment of Cystic Fibrosis, with Vertex coming to a long-term, extended, reimbursement agreement with the NHS. This final decision differs from its provisional draft guidance from November 2023 that recommended that the three drugs were above the acceptable range of NHS resources in terms of cost effectiveness, despite positive outcomes for Cystic Fibrosis patients.

While Leiden served as chairman, the market capitalization of Vertex Pharmaceuticals increased from $7.74 billion at the beginning of 2012 to $69.97 billion in April 2020.

On April 1, 2020, Leiden transitioned to the role of executive chairman. He was succeeded by Reshma Kewalramani, who was previously the company's chief medical officer. Leiden currently serves as executive chairman.

From Wikipedia’s article on Jeffrey Leiden (this version), CC BY-SA 4.0.

Personal life

  • BornOct 12, 1955, Chicago11 12
  • CitizenshipUnited States13

Philanthropy

In December 2017, Leiden and his wife Lisa established a professorship in translational medicine at the Brigham and Women’s Hospital and Harvard Medical School. The Leidens are also major donors to the Museum of Fine Arts, Boston, Ariadne Labs and the Bottom Line Foundation.

From Wikipedia’s article on Jeffrey Leiden (this version), CC BY-SA 4.0.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33